Indeed, combined anti-CTLA-4 and anti-PD-1 blockade can overcome the larger immune incline presented by less immunogenic cancers and associated poorer T cell activation resulting from exposure to low affinity antigens (Fig. 2) [17]. The gene discussed is CTLA4; the disease is cancer.